Prise en charge des patients de stade avancé avec remaniement ALK : aujourd'hui et demain (« qui sera un autre jour... »)

The management of advanced ALK adenocarcinomas has grown quite rapidly: from the discovery of this driver in 2007 to the presentation of alectinib at the ASCO congress in June 2017, only 10 years have passed, In which the management strategy for these particular diseases has only evolved. While the first line has long been based on crizotinib, future years will see the development of new generation ALK inhibitors on the front line. This article proposes to take up the therapies and strategies of “today” before discussing the options of “tomorrow”